Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) was up 7.56% at $24.20 on Monday, in a 52-week range of $9.80 to $25.00 and with a consensus analyst target price of $3.80. As for the mean price target, it implies downside of -83.11% from the $22.50 prior closing price. Paratek Pharmaceuticals, Inc. has a 650.50M market cap and its past year revenues were 0.05M. Going from the most negative analyst price target to above consensus is one thing. Now Paratek Pharmaceuticals, Inc.’s current price is $31.8 shy of the official highest sell-side analyst price target on Wall Street.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 57.14% since January and is up 10.50% for the past week. The share price of PRTK has increased by over 72.86% in the last six months. This increase is typical for the uptrend and shows the considerable optimism among investors.
A look at some of the inputs to technical analysis model shows how Paratek Pharmaceuticals, Inc. current price compares to its recent moving averages. Paratek Pharmaceuticals, Inc. is currently trading 14.75% above its 20-day and 49.33% versus the 200-day simple moving averages while 11.51% compared with its 50-day simple moving average. Additionally, Paratek Pharmaceuticals, Inc. (PRTK) stock price has gone up by 13.08% over the last 20 trading days, and its price is -3.20% below the 52-week high.
The Average True Range indicator applied to a daily chart of Apple has a current ATR reading of 1.03. This gives traders an indication of how much volatility or movement they can expect each day. Average True Range looks at the distance the price is traveling each day and plots it on a graph. The ATR reading can then be used by traders to determine when markets are most likely to range, when there is a high interest in a trend, or when extreme levels are being reached indicating a reversal.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares were last seen up 7.71% at $0.60, which is 167.86% higher than the previous trading session. The 52-week range is $0.28 to $0.77 and the consensus target price is $1.50. The company has a market cap of $177.00M and its 12 month revenue was almost $58.50M. The stock has been upbeat for quite some time as is up 6.31% for the last 20 trading days, and now the firm’s performance is turning out to be bullish with a 9.69% gain for the week. It has gain by over 42.93% in the last twelve months.
Going from the most bullish analyst price target to below consensus is one thing. Now Peregrine Pharmaceuticals, Inc. $1.50 target price is just $0.5 shy of the official lowest sell-side analyst price target on Wall Street. It looks like analysts are feeling bullish about the stock with overall sell-side analysts calling it a not a Buy. Their price objective ranges between $1.00 and $2.00.
For a profitability analysis, there is the 38.10% gross margin and the -65.90% net margin to consider. According to the past 5 years report, the company on average reported 13.10% year-over-year EPS growth and sales growth was recorded at 27.10%. Its quick ratio was 0.70 while current ratio was noted as 1.20 in the most recent quarter.